Abstracts tagged "gout"

Abstract Number: 1217 • 2019 ACR/ARP Annual Meeting
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Rehan Azeem¹, Alan Kivitz ², Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long-term treatment focuses on reducing serum uric…
Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Ruriko Koto¹, Akihiro Nakajima ¹, Hideki Horiuchi ¹ and Hisashi Yamanaka ², ¹Teijin Pharma Limited, Chiyoda-ku, Tokyo, Japan, ²Sanno Medical Center, Minato-ku, Tokyo, Japan
Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…
Abstract Number: 25 • 2019 ACR/ARP Annual Meeting
Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis
Yong-Wook Park¹, Young-Nan Cho ¹, Hae-Seong Jeong ¹, Hye-Mi Jin ¹ and Seung-Jung Kee ¹, ¹Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are subsets of innate invariant T cells and rapidly produce Th1/Th17 cytokines including interferon (IFN)-γ, tumor necrosis factor (TNF)-α,…
Abstract Number: 342 • 2019 ACR/ARP Annual Meeting
Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout
Naomi Schlesinger¹, N. Lawrence Edwards ², Sanders Clark ³ and Peter Lipsky ⁴, ¹Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Department of Medicine, University of Florida, Gainesville, FL, ³HVH Precision Analytics, LLC, Wayne, PA, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Gout is one of the most common inflammatory arthropathies, although care of gout patients is not always optimal. By searching a large administrative data…
Abstract Number: 1218 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Rehan Azeem¹, Justin Park ¹, Horacio Plotkin ¹, Alan Kivitz ², Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of…
Abstract Number: 2053 • 2019 ACR/ARP Annual Meeting
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Soo-Kyung Cho¹, Jun Liu ² and Seoyoung C. Kim ², ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Gout is a common inflammatory arthritis, characterized by hyperuricemia leading to crystallization of uric acid in joints. Proinflammatory cytokines have been known as an…
Abstract Number: 154 • 2019 ACR/ARP Annual Meeting
Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting
Nicholas Lebedoff¹, Andrea Barker ², Curry L. Koening ³, Christina Gallop ⁴, Kelly Starman ⁵ and Michael Battistone ⁶, ¹University of Utah, Salt Lake City, ²Salt Lake City Veterans Affairs Medical Center & University of Utah, North Salt Lake, UT, ³University of Utah Hospital, Salt Lake City, UT, ⁴Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, ⁵Salt Lake City Veterans Affairs Medical Center, Salt Lake City, ⁶Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, UT
Background/Purpose: Gout is common in primary care, though patients often have inadequate control or are referred to specialists for evaluation and management. This may be…
Abstract Number: 343 • 2019 ACR/ARP Annual Meeting
Emergency Department Length of Stay in Patients with Acute Gout
Nadine Mbuyi¹, Steven Reinert ², Ross Hilliard ³, Anthony Reginato ³ and Deepan Dalal ³, ¹George Washington University, Washington, DC, ²Lifespan Health System, Providence, RI, ³Brown University, Rhode Island Hospital, Providence, RI
Background/Purpose: Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay…
Abstract Number: 1220 • 2019 ACR/ARP Annual Meeting
How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials
Sarah Stewart¹, Amy Tallon ², William Taylor ³, Angelo Gaffo ⁴ and Nicola Dalbeth ², ¹University of Auckland, Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Otago, New Zealand, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Prevention of gout flares is a central concern to patients with gout. There are many potential ways that gout flares could be reported in…
Abstract Number: 2054 • 2019 ACR/ARP Annual Meeting
Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database
Jinsu Park¹, Jung-Soo Song ², Minjin Kang ³ and Chan Hee Lee ⁴, ¹Division of Rheumatology, Department of International Medicine, National Health Insurance Service Ilsan hospital, Goyang-si, Republic of Korea, ²Chung-Ang University College of Medicine, Seoul, Republic of Korea, ³Research and analysis Team, NHIS Ilsan hospital, Goyang-si, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Background/Purpose: Gout is the most common inflammatory arthritis that results from chronic elevation of uric acid levels above the saturation point for monosodium urate crystal…
Abstract Number: 257 • 2019 ACR/ARP Annual Meeting
Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
Jasvinder Singh¹ and john Cleveland ², ¹University of Alabama Medical Center, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Alcohol abuse and associated mortality is an important public health problem in the U.S. To our knowledge, limited data are available on alcohol use…
Abstract Number: 346 • 2019 ACR/ARP Annual Meeting
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Chio Yokose¹, Na Lu ², Michael Chen-Xu ³, Natalie McCormick ⁴, Michael Pillinger ⁵, Yuqing Zhang ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Capital and Coast District Health Board, Wellington, New Zealand, ⁴Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁵New York University School of Medicine, New York
Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…
Abstract Number: 1226 • 2019 ACR/ARP Annual Meeting
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Daisy Vedder ¹, Martijn Gerritsen ¹, Mike Nurmohamed ², Ronald van Vollenhoven ³ and Christian Lood⁴, ¹Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴University of Washington, Seattle, WA
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has…
Abstract Number: 2058 • 2019 ACR/ARP Annual Meeting
Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016
Yu Pei Chock¹, Joseph Ross ¹, Lisa Suter ² and Taeho Greg Rhee ¹, ¹Yale School of Medicine, New Haven, ²Yale University/VA CT Healthcare System, New Haven
Background/Purpose: Studies show that gout treatment remains suboptimal in the United States (US). Despite clear benefits for urate-lowering therapy (ULT) for chronic gout, surveyed physicians…
Abstract Number: 871 • 2018 ACR/ARHP Annual Meeting
Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors
Tanya J. Major¹, Ruth Topless¹, Nicola Dalbeth² and Tony R. Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Hyperuricaemia (elevated serum urate) is a central risk factor for gout, an acute inflammatory form of arthritis. The balance between the hepatic production of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].